PCSA vs. RNAZ, IBIO, SHPH, TENX, PULM, CANF, KTTA, UPC, ASLN, and AIMD
Should you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include TransCode Therapeutics (RNAZ), iBio (IBIO), Shuttle Pharmaceuticals (SHPH), Tenax Therapeutics (TENX), Pulmatrix (PULM), Can-Fite BioPharma (CANF), Pasithea Therapeutics (KTTA), Universe Pharmaceuticals (UPC), ASLAN Pharmaceuticals (ASLN), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
TransCode Therapeutics (NASDAQ:RNAZ) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
In the previous week, Processa Pharmaceuticals had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for Processa Pharmaceuticals and 1 mentions for TransCode Therapeutics. Processa Pharmaceuticals' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.
TransCode Therapeutics' return on equity of -141.42% beat Processa Pharmaceuticals' return on equity.
Processa Pharmaceuticals received 3 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 85.71% of users gave TransCode Therapeutics an outperform vote while only 47.37% of users gave Processa Pharmaceuticals an outperform vote.
TransCode Therapeutics has a beta of -0.36, indicating that its stock price is 136% less volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
91.9% of Processa Pharmaceuticals shares are held by institutional investors. 1.5% of TransCode Therapeutics shares are held by company insiders. Comparatively, 22.2% of Processa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Processa Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
TransCode Therapeutics presently has a consensus target price of $480.00, indicating a potential upside of 23,900.00%. Processa Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 270.37%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe TransCode Therapeutics is more favorable than Processa Pharmaceuticals.
Summary
Processa Pharmaceuticals beats TransCode Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Processa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Processa Pharmaceuticals Competitors List
Related Companies and Tools
